News

3M beat analyst expectations on Q2 revenue and earnings while raising its full-year sales guidance, a positive signal for the industrial conglomerate's operational momentum. However, the company narrowed its FY26 EPS guidance range, suggesting caution about profit growth ahead—likely reflecting cost pressures, geopolitical uncertainty, or margin headwinds. For Australian investors, this matters because 3M is a major multinational with supply chain exposure across Asia-Pacific and influences industrial capex cycles globally; mixed guidance typically triggers sector rotation away from industrials into defensive names.

General Motors beat Q2 expectations and raised full-year 2026 guidance, signalling strong demand for North American pickup trucks and SUVs—the profit engines of the US auto industry. This is meaningful because it suggests consumer spending on big-ticket items remains resilient despite interest rate concerns, and that legacy automakers are holding their ground against EV competition through their traditional product lines. For Australian investors, this matters as it indicates US economic health and could support commodity prices (steel, aluminium) while signalling strength in global automotive supply chains where Australian manufacturers participate.

Novartis delivered Q2 results ahead of both earnings and revenue expectations, signalling solid operational momentum in the global pharmaceutical sector. The reaffirmation of full-year 2026 guidance suggests management confidence despite ongoing macro headwinds. For ASX investors with pharma exposure or healthcare funds, this provides a positive read on the sector's earnings trajectory, though the impact is contained to the individual stock and broader healthcare theme rather than systemic market drivers.

The S&P 500 earnings season is off to a strong start with 88% of reporting companies beating profit estimates, suggesting corporate fundamentals remain resilient despite economic headwinds. This breadth of beats across the index is positive for US equity markets and typically supports higher valuations. Australian investors should note that strong US earnings generally benefit ASX-listed multinationals and tech exposure, though the stronger USD from this risk-on sentiment could pressure the AUD exchange rate.

AMD shares rose on the back of a new Microsoft deal and broader chip sector recovery, with an upcoming product event likely to drive further investor interest. The timing matters for semiconductor stocks globally—a category that's been volatile but crucial for AI infrastructure. Australian investors should note that tech stocks on the ASX (including those with US semiconductor exposure) often move in tandem with US chip sentiment, so this recovery could provide some tailwinds for local tech portfolios.

US equity indices rose as investors positioned ahead of major technology company earnings reports, with semiconductor stocks rebounding from recent weakness. This reflects typical pre-earnings optimism in mega-cap tech—a sector that dominates both the S&P 500 and Nasdaq. Australian investors should watch these earnings closely as tech earnings drive global sentiment, influence the ASX 200, and affect the Australian dollar through risk appetite shifts.

Exodus is cutting 25% of its global workforce as part of a strategic shift toward payments processing, signalling a major operational restructure and pivot in business model. This kind of large-scale redundancy typically indicates the company is moving away from less profitable service lines and consolidating around core payments infrastructure—a common pattern in fintech as the sector matures and margins compress. Australian investors holding fintech exposure should monitor whether this reflects broader industry consolidation pressures or Exodus-specific challenges; similar moves by regional payment processors could signal headwinds for ASX-listed financial tech players.

Domino's Pizza added 209 stores globally, showing continued expansion momentum, but international same-store sales declined—a concerning signal for mature markets already saturated with locations. For Australian investors, this matters because Domino's operates significantly in Asia-Pacific, so international weakness could pressure earnings growth even as the store count grows. Watch whether management's guidance on pricing power and labour cost inflation holds up, as these are key drivers for franchise profitability in developed markets like Australia.

Samsung is cutting U.S. consumer electronics jobs and relocating its American headquarters to Texas, signalling a strategic shift in its North American operations. This reflects cost pressures and potential restructuring within the consumer electronics division, though Samsung's broader semiconductor and display businesses remain core operations. For Australian investors, this has limited direct impact unless holding Samsung shares, but it underscores ongoing consolidation pressures in global consumer electronics and potential headwinds for tech hardware demand in developed markets.

CFM International, the joint venture between GE and Safran that supplies engines to both Boeing and Airbus, is increasing production to match rising aircraft output—a sign the aviation industry's recovery from COVID disruption is accelerating. This matters because engine supply has been a bottleneck constraining aircraft deliveries; ramping CFM production suggests fewer delays ahead for both planemakers and their customers. For Australian investors, this supports confidence in the aerospace recovery cycle and could benefit local tier-1 suppliers in the defence and commercial aviation chains.

The semiconductor sector has fallen into bear market territory (down 20%+ from recent highs), but a Bank of America analyst is cautioning against panic selling, noting that chips often underperform in Q3 seasonally. This matters because semiconductor strength has been crucial to the recent AI-driven rally in tech stocks globally and on the ASX. Watch for whether this is a healthy consolidation ahead of expected demand recovery, or early signs that the AI capex boom may be cooling faster than expected—a distinction that would significantly impact the valuation of mega-cap tech stocks that Australian investors hold heavily.

Semiconductor stocks weighed on the Nasdaq this week, a sector closely watched by Australian tech investors given exposure through ETFs and super portfolios. Meanwhile, PayPal rallied sharply on reports of a potential takeover bid from Stripe, signalling investor appetite for consolidation in fintech. For ASX investors, moves in US chip stocks typically flow through to local tech holdings and the broader market sentiment; watch whether weakness in semiconductors signals cooling US demand or is temporary positioning ahead of earnings season.

Global tech stocks are under pressure following Netflix's underwhelming earnings report showing its slowest revenue growth in two years at 11.7%, despite stabilising engagement metrics. The broader sell-off has extended to semiconductors and the Nikkei 225, which is tracking its worst day since March and approaching technical correction territory after shedding 12% from recent highs. For Australian investors, this signals renewed caution on tech valuations and semiconductor exposure—key holdings in ASX portfolios—as the investment narrative shifts from growth acceleration to moderating returns and intensifying competition.

Alphabet shares dropped 4% following reports that delays to its Gemini AI product indicate Google is losing ground to competitors like OpenAI and Microsoft in the critical AI arms race. This matters because AI capability has become a key driver of tech valuations and competitive positioning in enterprise software and cloud services. Australian tech investors and growth-focused portfolios with exposure to mega-cap US tech should monitor whether Google can deliver on its AI roadmap—delays risk accelerating talent and investment flows to rivals, which could pressure both US and ASX-listed tech stocks.

Major US banks are signalling caution at the start of earnings season, suggesting the market's current valuation may not be justified by underlying economic conditions. This is significant because US bank commentary often reflects broader credit conditions and consumer health—if they're worried, it typically precedes broader market volatility. Australian investors should monitor this closely, as US earnings disappointments often trigger ASX selloffs, particularly in financials and tech-heavy indices that have already priced in strong growth.

General Electric raised its full-year profit guidance, signalling operational strength in its aerospace division—a bright spot for industrial earnings. However, the market punished the stock because order-book growth, which had been accelerating, is now decelerating, raising concerns about future demand sustainability. For Australian investors, GE's weakness reflects broader caution about defence and industrial cyclicals; watch whether this signals cooling momentum across aerospace suppliers globally, which could affect local engineering and manufacturing stocks exposed to the sector.

Abbott Laboratories beat Q2 earnings expectations and raised its full-year 2026 adjusted EPS guidance above consensus estimates, signalling confidence in operational performance and demand for its healthcare portfolio. This is a positive signal for the healthcare sector and could attract investors to large-cap pharma plays, though the direct impact on Australian markets is limited unless the move triggers broader sector rotation. Australian investors with US healthcare exposure or holdings in comparable ASX healthcare stocks (like $CSL) should note this as a positive sentiment indicator for the sector.

GE Aerospace delivered a strong Q2 earnings beat and raised full-year guidance, signalling robust demand in the aerospace sector as aviation recovery continues post-pandemic. This is positive for the broader industrial and defence supply chain, with ripple effects across related manufacturers and suppliers. Australian investors should note this reflects healthy global aerospace momentum, which supports local suppliers like Brambles and defence contractors, though direct exposure to GE Aerospace in Australian portfolios is limited.

UnitedHealth Group beat Q2 earnings expectations and raised its full-year 2026 EPS guidance, signalling confidence in the US health insurance and healthcare services sector. This is a positive signal for a major US healthcare bellwether, though the direct impact on Australian markets is limited given UnitedHealth's US-focused business model. Australian investors with US healthcare exposure or those tracking global market sentiment should note that strong US healthcare earnings can support broader market strength and potentially strengthen USD, which affects Australian import costs and currency hedging.

UnitedHealth Group, the US's largest health insurer, raised full-year profit guidance for the second time in 2024, signalling strong operational momentum and better-than-expected claims management. This is a positive indicator for the US healthcare sector's profitability, though it also reflects tightening insurance margins as claims normalise post-pandemic. Australian investors holding US healthcare exposure via ETFs like VAS or VHY will see a modest boost; locally, this highlights the competitive pressure Australian health insurers face and validates concerns about rising medical costs in developed markets.